<DOC>
	<DOCNO>NCT00338585</DOCNO>
	<brief_summary>The purpose study directly compare safety efficacy intra-thrombus alfimeprase 0.3 mg/kg placebo acute peripheral arterial occlusion ( PAO ) measure 30 day open vascular free surgery rate .</brief_summary>
	<brief_title>Study Alfimeprase 's Ability Dissolve Blood Clots Leg Help Prevent Need Surgery</brief_title>
	<detailed_description>There unmet medical need improve thrombolytic therapy acute peripheral arterial occlusion ( PAO ) . Currently use plasminogen activator result increase circulating level plasmin result systemic `` lytic state '' distinguish physiologic pathologic thrombosis . In general , mean plasminogen activator infusion duration great 24 hour order achieve successful thrombolysis problematic disease delay restoration arterial flow lead irreversible ischemic damage . A direct thrombolytic agent like alfimeprase , rapid mechanism action potentially safer bleed risk profile , could facilitate rapid restoration arterial flow avoidance open vascular surgery .</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>Age 18 old Arteriographically confirm acute PAO low extremity onset symptom within 14 day prior randomization Acute index limb ischemia classify SVS/ISCVS Class I IIa cause occlusion native artery and/or bypass graft ( vein prosthetic ) . Only Class I subject abrupt onset ischemic rest pain abrupt onset/progression lifestylelimiting claudication eligible Acute PAO need urgent surgical intervention restore arterial blood flow event unsuccessful thrombolytic therapy Available followup assessment Contraindication systemic anticoagulation History endovascular procedure open vascular surgery index limb within past 30 day History significant acute chronic kidney disease would preclude contrast angiography Known allergy contrast agent History heparin induce thrombocytopenia Participation study investigational device , medication , biologic , agent within 30 day prior randomization Any thrombolytic therapy within 5 day prior randomization Past participation alfimeprase trial Pregnant , lactating , actively menstruate woman woman childbearing potential use adequate contraceptive precaution Investigator inability advance guidewire index occlusion Any subject feature opinion investigator preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>PAO</keyword>
	<keyword>acute peripheral arterial occlusion</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>blood clot</keyword>
	<keyword>leg attack</keyword>
	<keyword>alfimeprase</keyword>
	<keyword>thrombus</keyword>
	<keyword>embolism</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>claudication</keyword>
	<keyword>thrombolytic</keyword>
	<keyword>thrombosis</keyword>
	<keyword>plasminogen activator</keyword>
	<keyword>arterial flow</keyword>
</DOC>